Do you want to participate in a study related to HIV & Aging? Explore a treatment that looks at whether an oral drug decreases inflammation.

UCLA Health | CARE Center
This study investigates whether the oral drug letermovir decreases inflammation in people who have both HIV and CMV (cytomegalovirus).

ELIGIBILITY CRITERIA:

- Age 40 or older
- HIV with undetectable viral load on HIV treatment for at least 48 weeks
- Positive for CMV (the study will perform the test)

For more information, please contact the UCLA study team:

(310) 843-2015 or CAREOUTREACH@mednet.ucla.edu*

*There are limits to the confidentiality of email communications. Do not include any sensitive health information if you choose to contact the study team via email.